drugset / Trial / NCT02462928
A Safety and Efficacy Study of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a safety and efficacy study of abicipar pegol in participants with neovascular age-related macular degeneration.
Timeline
- Start
- 2015-06-25
- Primary completion
- 2018-04-18
- Completion
- 2019-06-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abicipar pegol | Protein / enzyme biologic | 2 mg | Intravitreal |
| Comparator | Ranibizumab | Monoclonal antibody | 0.5 mg | Intravitreal |